Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma - Wikidata - awgldk - TriplyDB

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

http://www.wikidata.org/entity/Q36719221

about

Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments Once again, rare diseases provide a spotlight.Leveraging premalignant biology for immune-based cancer prevention.Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.HLA polymorphism and risk of multiple myeloma.Myeloma and Bone Disease.MGUS to myeloma: a mysterious gammopathy of underexplored significance.Gaucher disease: Progress and ongoing challenges.Type II NKT Cells and Their Emerging Role in Health and Disease.Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.Lysosomal Storage Disorders and Malignancy.Natural Killer T Cells in Cancer Immunotherapy The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial Glucosylsphingosine is a key biomarker of Gaucher disease.Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Sphingolipid metabolism in cancer signalling and therapy.Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.Antigen-mediated regulation in monoclonal gammopathies and myeloma.MGUS, lymphoplasmacytic malignancies and Gaucher disease: the significance of the clinical association.Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.Checkpoint Inhibition in Myeloma: Opportunities and Challenges

P2860

Q26744596-46FFABE9-D535-4DAD-9916-38FFB85506A9 Q28067032-DF040F4E-58DF-4917-9FED-D5E4FA4A27AD Q30235844-51A0901E-C1BD-4C27-9905-ADCBBC78168F Q33731837-B802D4C3-D8E1-46EE-8ED7-42E9E2CC469F Q37304964-3E1F216F-50BA-4FA5-9D22-0CE22B76A982 Q37402009-0D1A6780-DC93-456E-B5AA-9DC1482F3D99 Q37468338-FA392E1C-ECC2-471F-805E-4E97377C20FF Q38598342-E31BEDA4-6F96-4FDD-855B-1FC343FD0201 Q38979865-DA4C107E-4A5E-48EC-90BD-07842A837615 Q39028972-F239B368-A574-4CB2-BD18-D986F900D6B7 Q39099635-8E3A7F07-3BC2-4D30-9D7A-DFE664D0BDDC Q41924097-24EA80C5-F85D-4D56-91C2-91EE492CA2B8 Q41971408-9B02A17D-6A9B-464B-9A0B-204C8A7528FB Q42078314-04050453-48D9-46BA-ACA9-BC29B23EA055 Q42223734-1F87591F-4CD7-49FE-9F9B-5C13AE2B2018 Q42733053-F1E7D12F-F62B-4551-B391-01A41C9F21E8 Q43008509-3F890AB5-FB96-4FE7-B979-44609B1C7AC9 Q47132349-92381F04-E6F9-4010-B72F-4C445DCF22DB Q49950035-C50CDE05-1B41-439E-8CA5-E0C4E5A15DAE Q51127427-C6CFBDEF-6788-4D71-AB17-2EBA22FE56B6 Q52369219-C14F9DC8-3F21-4502-92E5-C4D4B2C4BD8C Q52579670-C5A588B2-3769-4023-A3BE-3AF179D2EB69 Q52591049-4B6C06BF-94AF-4564-9F54-4CE6784E9D5C Q52646188-58AA2A0B-6AC1-430B-B732-B2255C387DF2 Q55267052-68F747E5-CA12-44C1-A4C2-A87094E65686 Q57491415-0EBCD67F-138C-41CE-A001-6BA8FFBBA43A

P2860

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

http://www.wikidata.org/entity/Q36719221

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@ast

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@en

type

label

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@ast

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@en

prefLabel

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@ast

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@en

P1433

Q36719221-12DC0C30-14F4-4F39-B755-CF1F59E74D53

P1476

Q36719221-E090BC90-2BEC-4C2E-9EE2-A61501A7548F

P2093

Q36719221-0EC2591E-E70D-4769-A7E8-E5CEB64B1316

Q36719221-577BDCBE-C3CB-411D-89DD-FDA55E570175

Q36719221-662EF326-1215-44E6-AEAD-E1769E9B032E

Q36719221-F3C1B9FC-ECA4-404E-AC74-43B5F7B4DDD3

Q36719221-FA35D360-6756-43EE-874A-E6255579CBD3

P2860

Q36719221-05922643-D5D2-40A6-B8D0-AAE59FFA990D

Q36719221-0ED74573-49EF-458B-A7C2-CBE17872BB41

Q36719221-28688160-A98D-44CB-902B-315517298583

Q36719221-355B2EC9-5674-4828-83AF-EB64350F0923

Q36719221-39258C2D-6AD5-4035-A677-0829F9FC8C9E

Q36719221-4A47A599-559B-45C4-84EA-2E6458A0D4FD

Q36719221-6207E378-064A-471D-BDED-2A1A684AA8E6

Q36719221-66983B7F-65A5-4D7D-8185-3C3FC3E99102

Q36719221-729FB72D-1EC0-49D4-A0F3-6B54C89E8472

Q36719221-742E2B2C-06CA-4E14-B430-71F2B7CCE88D

P304

Q36719221-EDDD4EC0-6B42-4180-888F-D3C54BE9A16C

P31

Q36719221-AAB5FF51-A646-4F1F-90B6-AD1A561A8B75

P356

Q36719221-03949847-A741-473E-B0D1-56848D9B8196

P407

Q36719221-0FF73B29-0A42-4901-8FD2-877C3B9767A9

P433

Q36719221-1179609C-D5EE-44A7-97BE-F128A10D8711

P478

Q36719221-36C63F73-33E3-40D3-B628-89A3F6A61047

P50

Q36719221-4FC019A1-D79F-46E7-9587-D5D69AAD2F1F

P577

Q36719221-6746626A-4751-4744-8148-26004D6EFF2F

P698

Q36719221-F56AC9EB-FBC4-4C46-BFF3-D391BA0C02CA

P932

Q36719221-3F8D01B4-6F97-4AC2-B8F8-659BF0FD531D

P356

P1433

The New England Journal of Medicine

P1476

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

@en

P2093

Chandra Sekhar Boddupalli

http://www.w3.org/2001/XMLSchema#string

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Madhav V Dhodapkar

http://www.w3.org/2001/XMLSchema#string

Pramod K Mistry

http://www.w3.org/2001/XMLSchema#string

Shiny Nair

http://www.w3.org/2001/XMLSchema#string

P2860

Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism

Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane)

Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study.

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women

Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.

Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation

Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer

P304

555-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1508808

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Branagan

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26863356

http://www.w3.org/2001/XMLSchema#string

P932

4804194

http://www.w3.org/2001/XMLSchema#string